B
asal cell carcinoma (BCC), although the commonest human cancer, had been subjected to relatively little molecular analysis until several years ago, when heritable mutations in PATCHED1 (PTC1) were found to underlie the basal cell nevus syndrome (MIM no. 109400) (Hahn et al, 1996; Johnson et al, 1996) , a rare autosomal dominant af¯iction characterized by multiple phenotypic abnormalities, including the development of multiple BCC starting in youth. PTC1 inhibits signaling by the membrane protein Smoothened (Smo) , and this inhibition is relieved by binding Sonic Hedgehog (SHH) to PTC. Unrestricted Smo signaling can affect target gene transcription via the GLI family of transcription factors (GLI1, GLI2, and GLI3). PTC1 is itself a target for HH signaling, thus forming a feedback loop in which decreased PTC1 protein function leads to the production of more PTC1 mRNA. In BCC, the feedback loop is disrupted because the increased mRNA encodes a nonfunctional PTC1 protein, and indeed PTC1 mRNA, as well as SMO, GLI1, and GLI3 mRNA, have been reported to accumulate in BCC. Other genes whose expression has been described to be activated by HH signaling in various tissues include members of the WNT/Wg and BMP/TGFb families of signaling molecules and the gene encoding the cell-surface HH-binding protein HIP (Dahmane et al, 1997; Ingham, 1998; Chuang and McMahon, 1999; Ghali et al, 1999) .
So far, it remains unclear how mutations in PTC1 and SMO and consequent changes in HH target gene expression produce the abnormal proliferation, differentiation, and adhesion characteristic of BCC tumor cells. As part of an effort to investigate this question, we have surveyed BCC for in vivo quantitative abnormalities of mRNA encoding hedgehog target genes, hemidesmosomal proteins, and a selection of genes that encode proteins important in apoptosis and cell cycle regulation.
MATERIALS AND METHODS
Aliquots of nodular BCC removed from the skin by curettage and normal human skin (obtained as part of breast reduction surgery) or epidermis (the roof of suction blisters of the volar forearm) were frozen immediately in liquid nitrogen and were stored at ±70°C until assayed or were ®xed and processed for routine microscopic examination. We used a Qiagen RNAeasy kit (Qiagen, Valencia, CA) to extract RNA from these tissues and from cultured normal cells [precon¯uent epidermal keratinocytes (HEK) grown in 0.07 mM Ca 2+ and ®broblasts] and cell lines (HaCaT, HeLa, and D259MG) . mRNA for PTC1, PTC2, GLI1, c-MYC, HIP, and GAPDH was quantitated by TaqMan. Primer and probe sequences are available as follows: Patched 1: forward (5¢-TCT TCA TGG CCG CGT TAA TC-3¢), reverse (5¢-TTG CAG GAA AAA TGA GCA GAA C-3¢), probe (5¢-FAM-AAT TCC CGC TCT GCG GGC G-TAMARA-3¢); Patched 2: forward (5¢-CCA GCA CCC CCT CAT CAG-3¢), reverse (5¢-GAC CCG AAG ACC AAT TCA GC-3¢), probe (5¢-FAM-CAC AAG GAG CGC CAC TGT CTG GAC-TAMARA-3¢); GLI1: forward (5¢-TGA GGC CCT TCA AAG CCC-3¢), reverse (5¢-GTA TGA CTT CCG GCA CCC TTC-3¢), probe (5¢-FAM-TGC TGG TGG TTC ACA TGC GCA GA-TAM-ARA-3¢); HIP: forward (5¢-TGC TAA GCC TCG CAT TCC A-3¢), reverse (5¢-ACA ACC CTA AGA ATG TGG TCA TGA-3¢), probe (5¢-FAM-TGT ATG TGT CCT ATA CCA CCA ACC AAG AAC GG-TA-3¢); c-Myc: forward (5¢-CAG CTG CTT AGA CGC TGG ATT-3¢), reverse (5¢-GAG GTC ATA GTT CCT GTT GGT GAA-3¢), probe (5¢-FAM-CTC CCG CGA CGA TGC CCC T-3¢); GADPH: forward (5¢-GAA GGT GAA GGT CGG AGT CA-3¢), reverse (5¢-GAA GAT GGT GAT GGG ATT TC 3¢), probe (5¢-FAM-CAA GCT TCC CGT TCT CAG CC±TAMARA-3¢). Ribonuclease protection assays (RPA) were performed using the Ambion RPAII kit according to the manufacturer's recommendations (Ambion, Austin, TX). Probes used for RPA were produced by polymerase chain reaction (PCR) ampli®cation of published sequences (GLI2, INTEGRIN b4), were purchased from Pharmingen or Ambion, or were generous gifts (PTC1, GLI1, INTEGRIN a6, and BPAG1 and BPAG2). DNA was linearized to give anti-sense probes of 150±300 bp and was labeled with a Promega (Madison, WI) transcription kit. Gels were scanned for quantitative densitometry using a BioRad (Hercules, CA) Model GS-670 imaging densitometer. The relative levels of three controls (``housekeeping'' genes ± GAPDH, ACTIN, and CYCLOPHILIN) were consistent in each sample, suggesting that none of the three changed signi®cantly in these samples. We identi®ed WNT family members expressed in HEK and in BCC by reverse transcription±PCR ampli®cation using consensus WNT family primers: forward (5¢-GGG GAA TTC CAR GAR TGY AAR TGY CAY-3¢, reverse (5¢-AAA ATC ATC TAG ARC ARC ACC ART GRA A-3¢) (Gavin et al, 1990) .
RESULTS
PTC Levels of PTC1 mRNA in all 27 BCC studied were elevated markedly compared with controls (epidermis, skin, or HEK) with a 15-fold variation among individual tumors. Levels were 10±500-fold higher by TaqMan and up to 1600-fold higher by RPA; however, PTC1 expression in the controls was very low, and consequently precise quantitation by RPA was dif®cult. Like those of PTC1, levels of PTC2 mRNA were high in BCC and were low in HEK; however, unlike those of PTC1, levels of PTC2 mRNA also were high in normal epidermis. Cultured dermal ®broblasts and HaCaT cells had uniformly low levels of PTC1 (albeit higher than the levels in HEK) and of PTC2 mRNA. D259MG cells, the cell line from which ampli®ed GLI1 originally was isolated, had low levels of PTC2 mRNA but, unlike other cultured cells studied, had elevated levels of PTC1 mRNAÐas high as those in BCC (Table I) .
GLI Levels of GLI1 message were elevated (vs that in HEK or skin) in all 12 BCC studied by TaqMan, the average level being approximately 1/6 that in D259MG cells (Table I) . In seven BCC studied by RPA, levels of GLI2 varied over a 9-fold range, were absent in HEK and in D259MG cells, but were as high in skin as in BCC.
HIP Of ®ve BCC tested by RPA three had mRNA levels 10-fold increased, and two had levels approximately 100-fold increased vs those in HEK. The levels in the two latter BCC were similar to that in D259MG cells. HIP expression was undetectable by RPA in extracts of normal skin (Fig 1) . In ®ve BCC tested by TaqMan, HIP expression averaged 40-fold higher than in normal skin and nearly 300-fold higher than in epidermis or HEK ( Table I) .
WNT genes By cloning reverse transcription±PCR product prepared from RNA, we found ®ve different WNT family members (2, 2b, 4, 5a, and 7b) to be expressed in cultured HEK and/or BCC, of which WNT7b was found the most commonly. By RPA WNT2b and 5a were undetectable to very low in HEK and skin but clearly were expressed in BCC, albeit at varying levels. By contrast, WNT4 was expressed in epidermis and skin but not in BCC (or in HEK). WNT7b was detected readily in all BCC, epidermis, and skin but was undetectable in HEK. WNT2 expression was highly elevated in one of ®ve BCCs studied but was undetectable by RPA in HEK.
c-MYC Of eight BCC tested by RPA all had near-complete loss of c-MYC mRNA as compared with that in HEK, epidermis, or whole skin. D259MG cells also have low c-MYC mRNA, whereas levels in HeLa and HaCaT cells are at least as high as those in HEK (Fig 2) . With Taqman, c-MYC expression is very high in epidermis and at least 15-fold lower in BCC ( Table I) .
BMP mRNA for BMP2 and BMP4 were detectable at similar levels in BCC, skin, and epidermis. BMP2 and BMP4 expression levels were absent to very low in HEK.
Hemidesmosomal protein gene expression We assessed mRNA levels of the four major known components of hemidesmosomes in BCC. mRNA for BPAG1 and BPAG2 were readily detectable in BCC and were present at levels similar to those in HEK or whole skin. a6 and b4 integrin mRNA are visible as faint bands in RPA of extracts of BCC, normal skin, or epidermis and are expressed at much higher levels in HEK. The single BCC with high a6 integrin expression did not differ clinically or histologically from those with lower expression.
Other Levels of expression of several genes involved in cell cycle regulation (p53, Rb, p21, and cdk4) and in control of apoptosis (bclx, bax, and mcl) varied among individual tumors and were not markedly different from those of skin. One consistent change seen was an at least 100-fold decrease in mRNA for c-FOS in BCC (n = 8) vs in normal skin (Fig 3) , a ®nding that is consistent with previous reports of high levels of c-FOS expression in adult human skin, especially in suprabasal cells, and reduced levels in BCC (Basset-Seguin et al, 1990; Takahashi et al, 1994) .
DISCUSSION
These data are consistent with the growing evidence that hedgehog target gene activation is the pivotal step in BCC carcinogenesis and is the ®rst study of the levels of expression of GLI2, WNT, BMP, c-MYC, and HIP in BCC. Furthermore, we have generated quantitative data regarding the degree to which the message for three HH-regulated genes accumulate in these tumors: PTC1, GLI1, and HIP mRNA levels are at least 50±100-fold increased in vivo in BCC; levels that we have found to be matched in vitro only by the levels in D259MG cells, in which GLI1 is highly ampli®ed. The uniformity of this upregulation of PTC1 mRNA in BCC indicates that loss of PTC1 protein function rarely is due to deletions of both genomic copies, production of unstable mRNA, or prevention of transcription of PTC1 message. The PTC2 levels that we detected con®rm those seen by in situ hybridization (Carpenter et al, 1998; Zaphiropoulos et al, 1999) . The lack of upregulation of PTC2 expression by ampli®ed GLI1 in D259MG cells, like the maintenance of PTC2 expression in the lung and skin of Shh ±/± mouse embryos (Pepicelli et al, 1998; St-Jacques et al, 1998) , is consistent with the conclusion that, at least in these tissues, PTC2 expression is not an HH target gene. Overexpression of GLI1 or GLI2 in the epidermis of transgenic mice can drive the development of BCC (Grachtchouk et al, 2000; Nilsson et al, 2000) . Our ®nding of levels of GLI1 that were upregulated consistently, of levels of GLI2 mRNA that were less consistent and on average were no higher than in normal skin, and of stronger RPA bands with GLI1 than GLI2 all suggest that GLI1 may be more important in vivo in driving the aberrant cell behavior characteristic of BCC. We have no information, however, regarding possible post-translational activation of these proteins in epidermis, and so the primacy of GLI1 must be considered a tentative conclusion.
HIP is a gene recently identi®ed in a cell-free screen for murine genes encoding proteins that bind Shh. It is present at the cell surface where it binds Shh with an avidity similar to that of PTC1, is a transcriptional target of Shh signaling during mouse development, and appears to attenuate Shh signaling, most likely by binding Shh and thereby reducing its interaction with Ptc1 (Ingham, 1998) . Our ®nding of high levels of HIP mRNA in BCC indicates that its expression is an in vivo target of HH signaling in humans as well as in mice.
The repertoire of WNT genes expressed in adult human epidermis has not previously been explored systematically. Saitoh et al (1998) analyzed WNT expression in adult murine epidermis using a strategy similar to ours: cloning of PCR product ampli®ed from WNT consensus primers followed by RPA quantitation. They found clones of Wnt4, 7a, and 10b, expression only of Wnt4 and 10b in epidermis, and of Wnt4 in newborn mouse epidermal keratinocytes in culture. We cloned sequences corresponding to WNT2b, 4, 5a, and 7b from cDNA prepared from cultured HEK and to WNT2, 2b, 4, 5a, and 7b from cDNA prepared from BCC. Levels of WNT2 expression measured by RPA were low to undetectable in HEK. Expression of WNT2b, 5a, 7b and 13 were readily detectable in BCC. Human (like mouse epidermis) does express WNT4 but this WNT is undetectable in BCC. As the bulk of the cells in these samples were tumor cells, most likely the WNT messages detected in BCC were derived from the malignant cells rather than from``contaminating'' normal stromal cells, but con®rmation of this conclusion must await in situ studies. The expression of multiple WNT genes detectable at low levels by RPA is reminiscent of reports of similar studies in breast cancers (Huguet et al, 1994) , and different WNT have been described as having varying transforming potencies (Wong et al, 1994) .
One intracellular pathway by which Wnt signaling proceeds is via stabilization of b-catenin, which interacts with the Tcf-Lef family of transcription factors to affect gene expression. Stabilization of b-catenin protein by mutations in the b-catenin gene in keratinocytes produce pilomatrixomas, a skin tumor distinct from BCC (Chan et al, 1999) . Stabilization of b-catenin protein in colon cancer cells, often by mutations in APC, is associated with upregulation of c-MYC expression (He et al, 1998) . In contrast, despite their upregulation of WNT2b and 5a and hence potential b-catenin stabilization, we have found that BCC have c-MYC downregulation as compared either to skin or to cultured normal HEK. Different WNT species clearly affect the phenotype of cells differently, as manifested both by their different patterns of expression in normal vs malignant cells and also by their differing abilities to stabilize b-catenin and to transform, e.g., mammary epithelial cells in which speci®c model WNT4, 5a, and 7b have no effect (Shimizu et al, 1997) , and it is possible that different WNT produce different effects on c-MYC expression as well.
BCC have been suggested to arise from epidermal stem cells that are located in the bulge region of the hair follicles. That postulate is based not only on the continued proliferation and resistance to differentiation of BCC cells but also on their frequent expression of antigens similar to those expressed by the cells of the hair follicle bulge region, e.g., keratins 15 and 19 and a2, a3, and b1 integrins. Also consistent with this view is the observation that ptc +/± mice have upregulation of ptc promoter activity in the bulge cells as well as in BCC (Aszterbaum et al, 1999) . Epidermal stem cells express low levels of c-MYC despite their relatively high levels of b-catenin protein and despite the ability of exogenous stabilized b-catenin to enhance stem cell numbers in vitro (Zhu and Watt, 1999) . Upregulation of c-MYC expression can drive human epidermal stem cells into a transient amplifying phenotype (Gandarillas and Watt, 1997) , and most but not all studies report that c-MYC expression then is downregulated coincident with the onset of keratinocyte terminal differentiation. Consistent with these ®nd-ings, c-MYC expression in transgenic mice recently was found to drive epidermal keratinocyte proliferation and to inhibit normal complete differentiation in vivo (Pelengaris et al, 1999; Waikel et al, 1999) . Hence, at least in their failure to switch from proliferation to differentiation and their downregulation of c-MYC, BCC resemble epidermal stem cells. Of note, however, the putative epidermal stem cells of the hair follicle bulge, unlike BCC, do express a6 and b4 integrins and bullous pemphigoid proteins. Thus we speculate that upregulation of expression of WNT2b and/or 5a (and/or downregulation of WNT4 expression) and a possible resultant downregulation of c-MYC expression may be a crucial pathway by which hedgehog target gene dysregulation produces at least some aspects of the BCC phenotype.
Our quantitation of hemidesmosomal protein mRNA levels suggests that the well-established loss of hemidesmosomal proteins in BCC may not be controlled by loss of mRNA for integrins a6 and b4 or BPAG1 or 2. However, in contrast to our results, others have found consistent loss of BPAG1 and 2 mRNA by reverse transcription±PCR in BCC (Chopra et al, 1998) .
The marked differences in gene expression between cultured and in situ keratinocytes complicate the choice of proper controls. Further, these differences are consistent with other data indicating that the response of cultured cells to the hedgehog ligand or to the loss of PTC is blunted (Fan et al, 1997) . Our ®nding of upregulated PTC1 and HIP in cells with ampli®ed GLI1 (D259MG cells) suggests that the block to the hedgehog response in cultured cells lies upstream of this transcription factor.
These ®ndings further validate the concept of the primary role of hedgehog target gene activation in BCC tumorigenesis and are consistent with previously elucidated pathways of hedgehog signaling. Considerably more work, however, will be necessary to elucidate which of these changes described or which other changes yet to be described will be found to be the key to the mechanism by which aberrant hedgehog signaling leads to aberrant BCC cell behavior and which will be found to be epiphenomena.
